证券日报网讯 1月14日，国药一致在互动平台回答投资者提问时表示，公司会根据经营需要，探索设备 技术革新，合理降低物流成本。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 1月14日，国药一致在互动平台回答投资者提问时表示，公司将根据业务发展需求，积极 引入先进生产力要素，优化物流环节，实现降本增效。 ...

英特集团公告称，2026年1月10日至13日，"英特转债"转股2742590股，公司总股本由553004155股增至 555746745股。截至1月13日，控股股东浙江省医药健康产业集团有限公司及其一致行动人合计持股 322023393股，占最新总股本比例由58.23%降至57.94%，被动稀释触及1%整数倍。各主体持股比例均有 所被动下降，且本次变动不涉及履行承诺及违规情况。 ...

Group 1 - The stock of Luyuan Pharmaceutical declined by 7.46% with a turnover rate of 28.29% and a trading volume of 2.835 billion yuan, experiencing a fluctuation of 19.68% throughout the day [2] - Institutional investors net bought 191 million yuan while brokerage seats collectively net sold 1.6723 million yuan [2] - The stock was listed on the Shenzhen Stock Exchange's daily fluctuation board due to its 19.68% price change, with institutional special seats net buying 191 million yuan [2] Group 2 - The top five trading departments accounted for a total transaction of 559 million yuan, with a buying amount of 374 million yuan and a selling amount of 185 million yuan, resulting in a net buying of 189 million yuan [2] - Among the trading departments, four institutional special seats were present, with a total buying amount of 257 million yuan and a selling amount of 66.5 million yuan, leading to a net buying of 191 million yuan [2] - Over the past six months, the stock has appeared on the fluctuation board six times, with an average price increase of 4.26% the day after being listed and an average increase of 16.75% over the following five days [2] Group 3 - The stock experienced a net outflow of 238 million yuan in principal funds today, with a significant outflow of 146 million yuan from large orders and 9.207 million yuan from major orders [2] - In the past five days, the stock has seen a total net outflow of 770 million yuan in principal funds [2]

1月14日，药易购涨5.12%，截至发稿，报42.48元/股，成交2.63亿元，换手率10.47%，总市值40.64亿 元。药易购股价已经连续3天上涨，区间累计涨幅14.22%。 截至发稿，孔宪政累计任职时间5年50天，现任基金资产总规模56.08亿元，任职期间最佳基金回报 93.39%， 任职期间最差基金回报-16.74%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 资料显示，四川合纵药易购医药股份有限公司位于四川省成都市金牛区友联一街18号13层，成立日期 2007年4月28日，上市日期2021年1月27日，公司主营业务涉及院外市场的医药类产品批发及零售。主营 业务收入构成为：药品(化药)99.27%，其他(补充)0.73%。 责任编辑：小浪快报 从药易购十大流通股东角度 数据显示，诺安基金旗下1只基金位居药易购十大流通股东。诺安多策略混合A（320016）三季度新进 十大流通股东，持有股数56.4万股，占流通股的比例为0.92%。根据测算，今日浮盈赚取约116 ...

Core Viewpoint - The stock of Luyuan Pharmaceutical (002788) closed at 26.26 yuan on January 13, 2026, reflecting a decrease of 3.74% with a turnover rate of 13.56% and a trading volume of 517,800 lots, amounting to a transaction value of 1.392 billion yuan [1]. Group 1 - The company is committed to providing quality services to upstream and downstream clients in response to the cross-strait social security and medical insurance integration, although specific revenue projections were not disclosed [2]. - The company is adapting its operational strategies in accordance with national medical insurance reforms while ensuring compliance with regulatory requirements [3]. Group 2 - On January 13, the net outflow of institutional funds was 139 million yuan, while retail investors saw a net inflow of 137 million yuan [4][5]. - The trading data indicates a net inflow of 2.5962 million yuan from speculative funds on the same day [5].

Group 1 - The company is actively advancing its digital transformation by leveraging AI to enhance industrial upgrades [1] - The company has completed the privatization deployment of AI computing power and large models, and is implementing a unified AI capability platform [1] - The integration of AI is being applied internally in areas such as operations, risk control, marketing, finance, and logistics, while externally it is enhancing clinical auxiliary diagnosis applications in traditional Chinese medicine and specialized diseases [1]

Core Viewpoint - Luyuan Pharmaceutical (002788) is adapting its business strategies based on market feedback while strictly adhering to regulatory requirements to provide quality services to its upstream and downstream customers [1]. Group 1 - The company is responding to market feedback by adjusting its operational measures [1]. - The company emphasizes compliance with relevant regulatory requirements in its operations [1]. - The focus is on delivering high-quality services to both upstream and downstream clients [1].

证券日报网讯1月13日，嘉事堂（002462）在互动平台回答投资者提问时表示，截至2026年1月9日，公 司股东共3万6千余户。 ...

Group 1: AI Applications - Elon Musk announced the open-sourcing of the X recommendation algorithm, with the GEO (Generative Engine Optimization) concept gaining traction, focusing on content optimization strategies for large models [5] - DeepSeek is expected to release its latest flagship AI model in February, with Zhuoyi Information launching the SnapDevelop professional version, which includes an AI programming assistant supporting major AI models [6] - Zhuoyi Information's stock saw a maximum increase of 31.88% over two days, reflecting strong market interest in AI programming tools [6] Group 2: AI Marketing - JD.com launched an AI marketing agent named "Jingxiaotong," indicating a significant transformation in the marketing industry driven by digitalization and intelligence [9] - Institutions predict that the AIGC advertising market will grow tenfold to 150 billion yuan by 2030, with a global market size exceeding 100 billion USD and China's market reaching 24 billion yuan [9][10] - Yidian Tianxia, a company with over ten years of partnership with Google, has seen its stock rise by 71.44% over three days, benefiting from its early positioning in GEO business [10] Group 3: AI Healthcare - NVIDIA and Eli Lilly plan to invest $1 billion over five years to establish an AI drug laboratory, aiming to accelerate medical discoveries [13] - OpenAI's release of ChatGPT Health targets the trillion-dollar AI healthcare market, with institutions identifying healthcare as a key application area for AI [13][15] - The Chinese AI healthcare market is projected to grow from 8.8 billion yuan in 2023 to 315.7 billion yuan by 2033, with a compound annual growth rate of 43.1% [21] Group 4: Commercial Aerospace - The successful suborbital flight test of the Li Hong No. 1 remote sensing vehicle by China Aerospace Science and Technology Corporation marks a significant achievement in commercial aerospace [23] - Jieli Suojun, a traditional rigging leader, reported a 397.1% year-on-year increase in net profit for the first three quarters of 2025, driven by new business expansions and structural optimization [24] - The company has transitioned from providing general rigging to becoming a key subsystem in rocket solutions, indicating strong market positioning in the commercial aerospace sector [24] Group 5: Photovoltaic and Space Technology - Junda Co. is focusing on photovoltaic batteries, with over half of its business coming from overseas, and is strategically investing in satellite battery companies to enter the space photovoltaic market [26] - The company's products have achieved over 33% efficiency, and it has completed principle verification in flexible perovskite aerospace applications [26] - Junda's stock has risen by 40.51% over five days, reflecting investor confidence in its growth potential in the space technology sector [26]